RETA | Reata Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	172.32 - 172.46
52 Week Range	21.83 - 172.46
Beta	0.93
Implied Volatility	11.87%
IV Rank	0.97%
Day's Volume	1,909,215
Average Volume	954,093
Shares Outstanding	38,097,300
Market Cap	6,566,450,628
Sector	Healthcare
Industry	Biotechnology
IPO Date	2016-05-26

Valuation
Profitability
Growth
Health
P/E Ratio	-66.29
Forward P/E Ratio	-3.72
EPS	-2.60
1YR Price Target	57.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	321
Country	USA
Website	RETA

Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.

RETA's peers: ABCL, ACAD, AKRO, ALNY, AUPH, AXSM, BLUE, CPRX, ETNB, EXEL, GALT, IBRX, IONS, MRNA, NVO, ONCY, PTCT, REGN, SAGE, SAVA, SRPT, TGTX, VIR, VKTX, VRTX

*Chart delayed

Analyzing fundamentals for RETA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is very poor, Growth is desperately bad and Health is weak. For more detailed analysis please see RETA Fundamentals page.

Watching at RETA technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on RETA Technicals page.